New hope for tough blood cancers? early trial tests LYT-200

NCT ID NCT05829226

Completed Disease control Sponsor: PureTech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called LYT-200 in 101 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had come back or stopped responding to treatment. The main goals were to check the drug's safety and find the right dose. While not a cure, the study looked for signs that the drug might help control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML, ADULT RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML, ADULT RECURRENT MDS

Contacts and locations

Locations

Baptist Health South Florida-Miami Cancer Institute

Miami, Florida, 02114, United States
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Mass. General Hospital-Harvard

Boston, Massachusetts, 02114, United States
Norton Healthcare-Norton Cancer Institute

Louisville, Kentucky, 40207, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States
University of California Irvine Medical Center

Orange, California, 92868, United States
Virginia Commonwealth University Medical Center

Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.